Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12857/115429
Title: Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells
Authors: Morgillo, Floriana
Della Corte, Carminia Maria
Diana, Anna
Mauro, Concetta di
Ciaramella, Vincenza
Barra, Giusi
Belli, Valentina
Franzese, Elisena
Bianco, Roberto 
Maiello, Evaristo
de Vita, Ferdinando
Ciardiello, Fortunato
Orditura, Michele
Keywords: AKT;breast cancer;ipatasertib;novel drugs;taselisib
Keywords Plus: AKT INHIBITOR GDC-0068;PIK3CA MUTATIONS;RESISTANCE;PATHWAY;GROWTH;PTEN;PI3K;METAANALYSIS;COMBINATION;METASTASIS
Issue Date: 2017
Publisher: IMPACT JOURNALS LLC
Journal: Oncotarget 
Abstract: 
The Phosphatidylinositol 3-kinase (PI3Ks) pathway is commonly altereted in breast cancer patients, but its role is still unclear. Taselisib, a mutant PI3Kα selective inhibitor, and ipatasertib, an AKT inhibitor, are currently under investigation in clinical trials in combination with paclitaxel or hormonal therapies in breast cancer. The aim of this study was to evaluate if PI3K or AKT inhibition can prevent resistance to chemotherapy and potentiate its efficacy.
URI: http://hdl.handle.net/20.500.12857/115429
DOI: 10.18632/oncotarget.20385
Appears in Collections:Articles

Show full item record

PubMed Central
Citations 50

13
Last Week
0
Last month
1
checked on Nov 28, 2021

SCOPUSTM   
Citations 5

14
checked on Aug 31, 2020

WEB OF SCIENCETM
Citations

15
checked on Nov 24, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.